Low-dose vaginal softgel is approved for treating moderate to severe dyspareunia associated with menopause.
Women in midlife with the most stress had the most benefit from mindfulness.
Dr. Richard-Davis served as the Scientific Program Chair of the 2018 NAMS Meeting. In this audiocast she highlights several clinical takeaways...
What works best for genitourinary syndrome of menopause: vaginal estrogen, vaginal laser, or combined laser and estrogen therapy?
There are not enough data to recommend laser therapy over the gold standard, transvaginal estrogen, for treating symptoms of the...
Age and previous hormone replacement therapy did not influence prasterone’s efficacy in treating dyspareunia.
Coverage and expert comment on new insights on HT and Alzheimer disease risk, HT route and sexuality outcomes, mortality in WHI participants, and...
Vitamin D supplementation does not appear to reduce the risk of falls or fracture or to improve bone mineral density.
What types of menopausal symptoms are breast cancer survivors faced with, and following breast cancer, what treatments should clinicians...
Women with osteopenia who received intravenous zoledronate had a significantly lower risk of fractures.
Dr. McClung also discusses long-term denosumab therapy
The risk of perimenopausal depression is estimated to be 45%-68%.